Syndicate content

Archive - Apr 18, 2015

Aethlon Subsidiary Exosome Sciences Collaborates with Boston University School of Medicine in Study Quantitating Exosomes That Can Carry Tau Protein Across the Blood-Brain Barrier; Part of DETECT Study of Biomarkers for CTE Looks at 78 Former NFL Players

In an April 16, 2015 press release, Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD) (http://www.aethlonmedical.com/), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced that Dr. Robert Stern, Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority-owned subsidiary, Exosome Sciences, Inc. (http://www.exosomesciences.com/) . The presentation was given on Apriol 16, 2015, at the 5th Annual Traumatic Brain Injury Conference that was held in Washington, D.C. The findings are part of the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) study, a research project funded by the National Institutes of Health (NIH), being conducted at BUSM's CTE Program. The DETECT study examines potential biomarkers for CTE (chronic traumatic encephalopathy) by studying a sample of former professional American football players and a control group of same-age men without any history of brain trauma from contact sport involvement. In connection with the DETECT study, researchers at Exosome Sciences have been applying proprietary techniques to isolate microscopic exosomes that transport CTE-associated tau protein (tausomes) across the blood-brain barrier. As part of the DETECT project at BUSM, blood samples from 78 former NFL players and 16 control subjects were analyzed by Exosome Sciences researchers. In the study, researchers were able to isolate and quantify the presence of tausomes in the blood. During his presentation, Dr. Stern reported that former NFL players' tausome levels were measured to be significantly higher than those of the control subjects.

Aethlon Announces Cancer Clinical Trial Agreement with UC Irvine to Assess Plasma Exosome Concentration in Cancer Patients Undergoing Treatment; Company Has Candidate Device to Reduce Presence of Circulating Tumor-Derived Exosomes

In an April 15, 2015 press release, Aethlon Medical, Inc. (OTCQB:AEMD) (http://www.aethlonmedical.com/), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; breast adenocarcinoma, colorectal, gastric & gastroesophageal, pancreatic, cholangiocarcinoma, lung (NSCLC), head & neck (SCC), melanoma, and ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier® as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis. Aethlon Medical believes that the Hemopurifier is a first-in-class bio-filtration device that targets the single-use removal of viruses and tumor-derived exosomes from the circulatory system. Recruitment of participants in the study will be through the use of internal and outside referrals to the University of California, Irvine Medical Center (UCIMC).

Achelios to Announce Results of Phase IIa Drug Trial of NSAID for Topical Treatment of Migraines

In an April 18, 2015 press release, Achelios Therapeutics (http://achelios.com/) announced that it will present, on April 22, 2015, results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN™, the company's proprietary topical anti-migraine therapy. The data to be presented demonstrate that the simple application of a well-known non-steroidal anti-inflammatory drug (NSAID), using the company's proprietary formulation, on the skin, over the trigeminal nerve branches, can be a safe and effective alternative treatment for patients suffering from acute migraine. William R. Bauer, M.D., Ph.D., FAAN, a neurologist and migraine headache specialist and advisor to Achelios, said, "Migraine remains a significant global cause of disability and disruption of activities of daily living. TOPOFEN results show promise to provide a safe and effective treatment that will positively impact the disabling effects of such a condition." The results of the clinical trial will be presented at the Emerging Science session of the American Academy of Neurology annual meeting in Washington, D.C., on Wednesday, April 22, 2015. The study was conducted by scientists from Achelios and the Michigan Headache & Neurological Institute in Ann Arbor, Michigan. Wolfgang Liedtke, M.D., Ph.D., from Duke University will present the results as a member of the team that conducted the research and a paid advisor to Achelios. Dr. Liedtke, an Associate Professor of Neurology and Attending Physician in the Duke Pain Medicine clinics, said, "The results of the study are encouraging, and those of us who treat migraine think it may lead to a meaningful alternative treatment for a substantial number of migraineurs.

Inflammation Plays Causal Role in Serious Nervous System Involvement Seen in 15% of Lyme Disease Patients; Anti-Inflammatory Steroid Dexamethasone Largely Effective Against Many of These NS Complications

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published online on April 16, 2015 in The American Journal of Pathology. The investigators at the Tulane National Primate Research Center and Louisiana State University Health Sciences Center also showed that the anti-inflammatory drug dexamethasone prevents many of these reactions. "These results suggest that inflammation has a causal role in the pathogenesis of acute Lyme neuroborreliosis," explained Mario T. Philipp, Ph.D., Professor of Microbiology and Immunology and Chair of the Division of Bacteriology and Parasitology at Tulane National Primate Research Center (Covington, Louisiana). Lyme disease in humans results from the bite of a tick infected with the spirochete Borrelia burgdorferi (Bb). As Bb disseminates throughout the body, it can cause arthritis, carditis, and neurologic deficits. When the nervous system is involved, it is called Lyme neuroborreliosis (LNB). Clinical symptoms of LNB of the peripheral nervous system may include facial nerve palsy, neurogenic pain radiating along the back into the legs and feet, limb pain, sensory loss, or muscle weakness. Central nervous system involvement can manifest as headache, fatigue, memory loss, learning disability, depression, meningitis, and encephalopathy. To understand further the neuropathologic effects of Bb infection, researchers infected 12 rhesus macaques with live B. burgdorferi; two animals were left uninfected as controls.

Unique Combination of Single Molecule Fluorescence Microscopy and Optical Trapping Reveals Structure & Function of Certain DNA Repair Proteins

By combining two highly innovative experimental techniques, scientists at the University of Illinois at Urbana-Champaign have, for the first time, simultaneously observed the structure and the correlated function of specific proteins critical in the repair of DNA, providing definitive answers to some highly debated questions, and opening up new avenues of inquiry and exciting new possibilities for biological engineering. Scientists who study biological systems at the molecular level have over the years looked to the structure of protein molecules--how the atoms are organized--to shed light on the diverse functions each protein performs in the cell. The inverse is also true: observing the specific work particular protein molecules perform has provided important clues as to the conformation of the respective molecules. But, until recently, our most advanced laboratory experiments could only investigate one at a time--static form or dynamic function--and from the results, deduce the other. This indirect method often doesn't provide definitive answers. Now, Illinois biological physicists Dr. Taekjip Ha and Dr. Yann Chemla have combined two cutting-edge laboratory techniques that, when used together, directly get at the structure-function relationship in proteins. Dr. Ha is well recognized for his innovative single molecule fluorescence microscopy and spectroscopy techniques. Dr. Chemla is a top expert in optical trapping techniques. Their combined method--simultaneous fluorescence microscopy and optical trapping--yields far more definitive answers to questions relating structure to function than either technique could independently. Working in collaboration, Dr. Ha and Dr. Chemla each applied the above techniques in their laboratories, with conclusive results.